Plexium focuses on targeted protein degraders to reinvent the way medicines are discovered.
The company's DELPhe platform, named for DNA-Encoded Library (DEL) phenotypic (Phe) screening, is a unique drug discovery engine designed to identify novel small molecules for multiple indications, including cancer and inflammatory disease indications.
- Swamy Vijayan, PhD
- Big news today – we closed a $35M financing w/ @Lux_Capital, Pivotal Bioventures, The Column Group, @DCVC and other… https://t.co/jtR1hty52Z
- Don’t miss Plexium CEO Kandaswamy Vijayan’s presentation on “Degrading ‘Undruggable’ Proteins with Molecular-Glues”… https://t.co/5laa8f2ZjD
- Plexium CEO Kandaswamy Vijayan to present on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” at the 2nd Tar… https://t.co/FHaec45GbH